The end of paper at Anvisa! Electronic Protocol is the future of Health Surveillance

RDC 954/2024 -Comprehending the Highlights and Impacts on Drug Registration

The Brazilian Health Surveillance Agency (ANVISA) will fully adopt the electronic document protocol from March 13, 2025, as established by RDC 947/2024. This change will eliminate the need for paper documents, promoting greater agility in document analysis, modernizing processes and reducing operating costs, especially those related to digitization and physical storage.

ANVISA Publishes Database for Clinical Investigations into Medical Devices

ANVISA Publishes Database for Clinical Investigations into Medical Devices

The National Health Surveillance Agency (ANVISA) has announced the launch of a database aimed at clinical investigations related to medical devices. This initiative represents an important milestone in the health sector, promoting greater transparency, efficiency and safety in research carried out in Brazil.

ANVISA Intensifies Monitoring of Generic Drugs: New Requirements in Force

ANVISA Intensifies Monitoring of Generic Drugs: New Requirements in Force

The National Health Surveillance Agency (Anvisa) recently announced a new package of regulatory measures aimed at strengthening the monitoring of generic drugs in Brazil. The aim is to ensure even greater safety and efficacy for these products, which are widely used by the population and represent a significant part of the national pharmaceutical market.